XML 47 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Collaboration Agreements and Revenues - Summary of License Revenue and Development Revenue Recognized under Agreement (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue $ 24,364 $ 42,888 $ 62,793 $ 67,288
License Revenue [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 0 0 0 0
Development Revenue [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 19,641 18,957 34,228 38,402
Astellas Agreement [Member] | License Revenue [Member] | Japan [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 0 0 0 0
Astellas Agreement [Member] | License Revenue [Member] | Europe [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 0 0 0 0
Astellas Agreement [Member] | Development Revenue [Member] | Japan [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 99 164 179 327
Astellas Agreement [Member] | Development Revenue [Member] | Europe [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 2,546 4,602 6,077 9,176
AstraZeneca Agreements [Member] | China [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 0 441 0 594
AstraZeneca Agreements [Member] | License Revenue [Member] | U.S./RoW and China [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue 0 0 0 0
AstraZeneca Agreements [Member] | Development Revenue [Member] | U.S./RoW and China [Member]        
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]        
Total revenue $ 16,993 $ 13,750 $ 27,969 $ 28,305